Of 69 enrolled patients with ALK-positive NSCLC pretreated with second-generation ALK TKIs, 59 patients (85.5%) consented to data collection and initiated lorlatinib treatment—these patients comprised the lorlatinib cohort (Figure 1). The gene discussed is ALK; the disease is non-small cell lung carcinoma.